Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression
Long-Hai Wang,Braulio A. Marfil-Garza,Alexander U. Ernst,Rena L. Pawlick,Andrew R. Pepper,Kento Okada,Boris Epel,Navin Viswakarma,Mrignayani Kotecha,James Arthur Flanders,Ashim K. Datta,Hong-Jie Gao,Ye-Zi You,Minglin Ma,A. M. James Shapiro
DOI: https://doi.org/10.1038/s41551-023-01145-8
IF: 28.1
2023-12-06
Nature Biomedical Engineering
Abstract:Cellular therapies for type-1 diabetes can leverage cell encapsulation to dispense with immunosuppression. However, encapsulated islet cells do not survive long, particularly when implanted in poorly vascularized subcutaneous sites. Here we show that the induction of neovascularization via temporary controlled inflammation through the implantation of a nylon catheter can be used to create a subcutaneous cavity that supports the transplantation and optimal function of a geometrically matching islet-encapsulation device consisting of a twisted nylon surgical thread coated with an islet-seeded alginate hydrogel. The neovascularized cavity led to the sustained reversal of diabetes, as we show in immunocompetent syngeneic, allogeneic and xenogeneic mouse models of diabetes, owing to increased oxygenation, physiological glucose responsiveness and islet survival, as indicated by a computational model of mass transport. The cavity also allowed for the in situ replacement of impaired devices, with prompt return to normoglycemia. Controlled inflammation-induced neovascularization is a scalable approach, as we show with a minipig model, and may facilitate the clinical translation of immunosuppression-free subcutaneous islet transplantation.
engineering, biomedical